

Technology Advisory Committee HST Interests Register
Topic: Birch bark extract for treating epidermolysis bullosa [ID1505]
Publication Date: 20 September 2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Stuart Mealing	Committee Member	Non-financial professional	The company Stuart works for is currently doing some work for another company who are active in DEB (Krystal) and may submit to NICE in the future. This company is not a stakeholder for ID1505, and Stuart has had no personal input in that project or had any financial gain from it.	18/05/2023	N/A	It was agreed that Stuart's declaration would not prevent him from participating in discussions on this evaluation.
Sarah Davis	Committee Member	Non-financial professional	ScHARR-TAG (University of Sheffield) are acting as the EAG on this topic. I am a member of ScHARR-TAG, but I have had no involvement in their work on this topic.	18/05/2023	N/A	It was agreed that Sarah's declaration would not prevent her from participating in discussions on this evaluation.
Claire Mather	Patient Expert	Direct financial interest	Claire's nominating organisation has received a very small amount of funding from Amryt Pharma for one of their patients for members' family fundraise event and	20/09/2022	N/A	It was agreed that Claire's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			DEBRA also received some funding to support them with an insight survey.			
Dr Anna Martinez	Clinical Expert	Direct financial	Anna has been Principal Investigator for the study run by Amryt Pharma and has done some consultancy work for the company.	15/09/2022	N/A	It was agreed that Anna's declaration would not prevent her from providing expert advice to the committee.
Jemima Mellerio	Clinical Expert	Direct financial	Over the last 3 years Jemima has undertaken paid consultancy for Amryt Pharma, Krystal Biotech, Castle Creek Pharmaceuticals and ProQR therapeutics – all relating to potential therapies for EB.	20/09/2022	N/A	It was agreed that Jemima's declaration would not prevent her from providing expert advice to the committee.